News | Ablation Systems | October 14, 2015

AtriCure Enters Into Definitive Agreement to Acquire nContact

Complementary product lines to provide additional solutions for serious forms of atrial fibrillation

AtriCure, definitive merger agreement, nContact Inc., atrial fibrillation solutions, cardiac ablation

October 14, 2015 — AtriCure Inc. announced it has entered into a definitive merger agreement under which AtriCure has agreed to acquire nContact Inc., a privately held developer of innovative cardiac ablation solutions.

The transaction consideration consists of an upfront payment of approximately 3.7 million shares of AtriCure common stock, valued at $24.60 per share, and approximately $8 million in cash, subject to closing adjustments. The transaction also includes up to $50 million in additional contingent consideration based on completion of enrollment of the CONVERGE IDE trial and PMA approval. Additionally, nContact shareholders are entitled to additional sales-based contingent consideration on revenue in excess of an annual growth rate of greater than 25 percent through 2019. All contingent consideration can be paid in either cash or AtriCure common stock, or a combination of both.

The transaction will combine two companies focused on treatment of the most serious forms of atrial fibrillation and is expected to:

  • Expand AtriCure’s addressable market;
  • Complement and expand AtriCure’s current product portfolio and minimally invasive (MIS) intellectual property portfolio;
  • Enhance AtriCure’s commitment to clinical science with the CONVERGE IDE clinical trial;
  • Accelerate and sustain AtriCure’s revenue growth rate; and
  • Drive continued margin expansion and operating leverage opportunities.

nContact, based in Morrisville, North Carolina, develops and markets a portfolio of innovative devices that provide for less invasive ablation options for the treatment of cardiac arrhythmias. The company’s technology is used in the Convergent procedure, a multidisciplinary therapy in which a closed-chest surgical epicardial ablation is performed, and then complemented by an endocardial catheter ablation performed by an electrophysiologist.

nContact is currently conducting the CONVERGE IDE clinical trial, the first head-to-head study to evaluate the Convergent procedure versus catheter ablation in patients with persistent Afib. In addition to the ongoing IDE trial, individual center results have been published in numerous peer reviewed papers.

Subject to customary closing conditions, the transaction is expected to close in the next several weeks. AtriCure shareholder approval is not required.

For more information: www.atricure.com

Related Content

Leeds Hospital recently installed Philips Azurion angiography interventional labs to enhance procedural guidance capabilities.

Leeds Hospital recently installed Philips Azurion angiography interventional labs to enhance procedural guidance capabilities.

News | Cardiovascular Business | July 08, 2020
July 8, 2020 – Philips Healthcare and Leeds Teaching Hospitals NHS Trust announced a seven-year managed service agree
Medicare will pay for telehealth virtual doctor visits during the duration of the coronavirus COVID-19 outbreak.
News | Cardiovascular Business | March 17, 2020
March 17, 2020 — The Trump Administration today announced expanded Medicare telehealth coverage that will enable bene
Recognized as the “Pulitzer Prize of the business press,” the Jesse H. Neal Award finalists are selected for exhibiting journalistic enterprise, service to the industry and editorial craftsmanship
News | Cardiovascular Business | February 19, 2020
February 19, 2020 — Connectiv, a division of The Software and Information Industry Association (SIIA), has announced
 Cath Lab Philips Azurion angiography PCI
News | Cardiovascular Business | December 30, 2019
December 30, 2019 — Most patients do not understand or recall information given to them before heart procedures.
Siemens Healthineers Acquires ECG Management Consultants
News | Cardiovascular Business | November 11, 2019
November 11, 2019 — ECG Management Consultants, a leading U.S.
Videos | Cardiovascular Business | September 30, 2019
A discussion with Ruth Fisher, MBA, vice president of the...
Scranton Gillette Communications Names Diagnostic and Interventional Cardiology Group Publisher and Integrated Media Consultant

Diane Vojcanin (left) was named vice president, group publisher, healthcare group, overseeing Imaging Technology News (ITN) and Diagnostic and Interventional Cardiology (DAIC). Andreja Slapsys (right) was named a healthcare group integrated media consultant.

News | Cardiovascular Business | September 06, 2019
Business-to-business communications company Scranton Gillette Communications has named Diane Vojcanin as vice president...
FDA Opens Proposal Solicitation Period for 2020 Experiential Learning Program
News | Cardiovascular Business | July 17, 2019
The U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) announced the 2020...